SOLARA ACTIVE PHARMA (SOLARAPP1) | Financial Analysis & Statements
SOLARA ACTIVE PHARMA SCIENCES Small-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
3.2B
Gross Profit
1.7B
54.11%
Operating Income
334.4M
10.48%
Net Income
105.2M
3.30%
EPS (Diluted)
₹2.46
Balance Sheet Metrics
Total Assets
22.3B
Total Liabilities
11.3B
Shareholders Equity
11.0B
Debt to Equity
1.03
Cash Flow Metrics
Revenue & Profitability Trend
Quarter Income Flow
Jun 30, 2025
Annual Income Flow 2025
SOLARA ACTIVE PHARMA Income Statement From 2025 to 2025
| Metric | 2025 |
|---|---|
| Revenue | 12.4B |
| Cost of Goods Sold | 6.5B |
| Gross Profit | 6.0B |
| Gross Margin % | 48.0% |
| Operating Expenses | |
| Research & Development | - |
| Selling, General & Administrative | 492.9M |
| Other Operating Expenses | 1.6B |
| Total Operating Expenses | 2.1B |
| Operating Income | 1.1B |
| Operating Margin % | 9.0% |
| Non-Operating Items | |
| Interest Income | 7.6M |
| Interest Expense | 1.1B |
| Other Non-Operating Income | - |
| Pre-tax Income | 5.4M |
| Income Tax | 0 |
| Effective Tax Rate % | 0.0% |
| Net Income | 5.4M |
| Net Margin % | 0.0% |
| Key Metrics | |
| EBITDA | 2.0B |
| EPS (Basic) | ₹0.14 |
| EPS (Diluted) | ₹0.14 |
| Basic Shares Outstanding | 39898909 |
| Diluted Shares Outstanding | 39898909 |
Income Statement Trend
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
SOLARA ACTIVE PHARMA Balance Sheet From 2025 to 2025
| Metric | 2025 |
|---|---|
| Assets | |
| Current Assets | |
| Cash & Equivalents | 39.5M |
| Short-term Investments | 125.2M |
| Accounts Receivable | 3.3B |
| Inventory | 3.2B |
| Other Current Assets | 677.7M |
| Total Current Assets | 7.3B |
| Non-Current Assets | |
| Property, Plant & Equipment | 8.0B |
| Goodwill | 7.6B |
| Intangible Assets | 298.0M |
| Long-term Investments | - |
| Other Non-Current Assets | 71.2M |
| Total Non-Current Assets | 15.0B |
| Total Assets | 22.3B |
| Liabilities | |
| Current Liabilities | |
| Accounts Payable | 2.5B |
| Short-term Debt | 6.6B |
| Current Portion of Long-term Debt | - |
| Other Current Liabilities | 42.4M |
| Total Current Liabilities | 9.4B |
| Non-Current Liabilities | |
| Long-term Debt | 1.3B |
| Deferred Tax Liabilities | - |
| Other Non-Current Liabilities | 489.2M |
| Total Non-Current Liabilities | 1.9B |
| Total Liabilities | 11.3B |
| Equity | |
| Common Stock | 402.5M |
| Retained Earnings | -3.2B |
| Treasury Stock | - |
| Other Equity | - |
| Total Shareholders Equity | 11.0B |
| Key Metrics | |
| Total Debt | 8.0B |
| Working Capital | -2.2B |
Balance Sheet Composition
SOLARA ACTIVE PHARMA Cash Flow Statement From 2025 to 2025
| Metric | 2025 |
|---|---|
| Operating Activities | |
| Net Income | 5.4M |
| Depreciation & Amortization | - |
| Stock-Based Compensation | 26.8M |
| Working Capital Changes | 624.5M |
| Operating Cash Flow | 1.7B |
| Investing Activities | |
| Capital Expenditures | 3.8M |
| Acquisitions | 9.6M |
| Investment Purchases | - |
| Investment Sales | - |
| Investing Cash Flow | 23.6M |
| Financing Activities | |
| Share Repurchases | - |
| Dividends Paid | - |
| Debt Issuance | 750.0M |
| Debt Repayment | -1.1B |
| Financing Cash Flow | -623.6M |
| Free Cash Flow | 1.7B |
| Net Change in Cash | 1.1B |
Cash Flow Trend
SOLARA ACTIVE PHARMA Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
300.92
Price to Book
1.05
Price to Sales
1.66
PEG Ratio
-1.02
Profitability Ratios
Profit Margin
-1.52%
Operating Margin
3.37%
Return on Equity
0.05%
Return on Assets
0.02%
Financial Health
Current Ratio
0.92
Debt to Equity
51.38
Beta
0.84
Per Share Data
EPS (TTM)
₹-4.82
Book Value per Share
₹293.20
Revenue per Share
₹231.18
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| SOLARAPP1 | 20.8B | 300.92 | 1.05 | 0.05% | -1.52% | 51.38 |
| Sun Pharmaceutical | 3.9T | 36.73 | 5.15 | 15.08% | 19.21% | 6.68 |
| Divi's Laboratories | 1.7T | 67.11 | 10.82 | 14.64% | 24.04% | 0.58 |
| Sun Pharma Advanced | 46.7B | -13.65 | -13.55 | 157.88% | -53.22% | -1.21 |
| Innova Captab | 41.4B | 31.20 | 4.05 | 13.37% | 8.85% | 32.95 |
| Aarti Drugs | 34.0B | 16.37 | 2.43 | 12.28% | 8.03% | 39.05 |
Financial data is updated regularly. All figures are in the company's reporting currency.